Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xiamen Amoytop Biotech CoSHSE:688278 +2.94%75 Gross Margin % is 89.45% as of Mar. 2026, which is 0% above its 10-year median of 89.04. GuruFocus rates SHSE:688278 with a GF Score™ of 75/100 and a GF Value™ of ¥106.91 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 732 Biotechnology companies, Xiamen Amoytop Biotech Co ranks better than 87.84% on this metric.
Xiamen Amoytop Biotech Co (SHSE:688278) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Xiamen Amoytop Biotech Co had a gross margin of 89.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Xiamen Amoytop Biotech Co Gross Margin % Related Terms
Xiamen Amoytop Biotech Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688278 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiamen Amoytop Biotech Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Xiamen Amoytop Biotech Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Xiamen Amoytop Biotech Co (SHSE:688278) has a Gross Margin % of 89.45% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Xiamen Amoytop Biotech Co and its competitors. This is near median its historical median of 89.04. Over the past decade, Xiamen Amoytop Biotech Co's Gross Margin % has ranged from 87.10 to 93.49. According to the industry distribution chart, Xiamen Amoytop Biotech Co ranks #89 out of 732 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Xiamen Amoytop Biotech Co's Gross Margin % too high?
Xiamen Amoytop Biotech Co's current Gross Margin % of 89.45% is near median its 10-year median of 89.04. Over the past 10 years, this metric has ranged from a low of 87.10 to a high of 93.49. The Biotechnology industry median Gross Margin % is 60.92. Xiamen Amoytop Biotech Co's value of 89.45% is 46.8% above this industry median. Based on the distribution chart, Xiamen Amoytop Biotech Co ranks #89 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xiamen Amoytop Biotech Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xiamen Amoytop Biotech Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xiamen Amoytop Biotech Co ranks #89 out of 732 companies for Gross Margin %. This places Xiamen Amoytop Biotech Co in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Xiamen Amoytop Biotech Co's value of 89.45% is 46.8% above this benchmark. Historically, Xiamen Amoytop Biotech Co's own Gross Margin % has ranged from 87.10 to 93.49 over the past decade. While the company's 10-year median is 89.04 vs. the industry median of 60.92, Xiamen Amoytop Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xiamen Amoytop Biotech Co's current Gross Margin % of 89.45% is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Xiamen Amoytop Biotech Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xiamen Amoytop Biotech Co's current Gross Margin % is 89.45%, which is near median its own 10-year median of 89.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xiamen Amoytop Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co (SHSE:688278) is currently considered Possible Value Trap. The stock's GF Value™ is ¥106.91, compared to a current price of ¥60.63 — trading 43.3% below its estimated fair value. The current Gross Margin % is 89.45%, which is near median its 10-year median of 89.04 and 46.8% above the Biotechnology industry median of 60.92. Xiamen Amoytop Biotech Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Xiamen Amoytop Biotech Co (SHSE:688278), the current Gross Margin % is 89.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xiamen Amoytop Biotech Co (SHSE:688278) Overvalued in 2026?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co stock appears to be undervalued.
The current stock price of ¥60.63 is trading 43.3% below its estimated GF Value™ of ¥106.91.
GuruFocus considers Xiamen Amoytop Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688278:
Gross Margin %: 89.45% (near median its 10-year median of 89.04)
GF Value™: ¥106.91 vs. price of ¥60.63 (43.3% below fair value)
Industry Position: 46.8% above the Biotechnology median (#89 of 732)
No single metric tells the full story. See the SHSE:688278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
75GF Score
Get the complete analysis for SHSE:688278
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688278 has been successfully added to your 
